| Therapeutically significant microRNAs in primary and metastatic brain malignancies AA Balachandran, LM Larcher, S Chen, RN Veedu Cancers 12 (9), 2534, 2020 | 34 | 2020 |
| Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery N Subramanian, JR Kanwar, B Akilandeswari, RK Kanwar, V Khetan, ... Chemical Communications 51 (32), 6940-6943, 2015 | 28 | 2015 |
| Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry–based imaging N Subramanian, A Srimany, JR Kanwar, RK Kanwar, B Akilandeswari, ... Molecular Therapy-Nucleic Acids 5, 2016 | 27 | 2016 |
| Antisense oligonucleotide-mediated splice switching: potential therapeutic approach for cancer mitigation P Raguraman, AA Balachandran, S Chen, SD Diermeier, RN Veedu Cancers 13 (21), 5555, 2021 | 22 | 2021 |
| Targeting CD44, ABCG2 and CD133 markers using aptamers: In silico analysis of CD133 extracellular domain 2 and its aptamer N Subramanian, B Akilandeswari, A Bhutra, M Alameen, U Vetrivel, ... Rsc Advances 6 (38), 32115-32123, 2016 | 10 | 2016 |
| Targeting HMGA protein inhibits retinoblastoma cell proliferation A Balachandran, A Zambre, JS Kainth, LDN Selvan, S Parameswaran, ... RSC advances 8 (55), 31510-31514, 2018 | 6 | 2018 |
| Aptamer as therapeutics for cancer with focus on retinoblastoma N Subramanian, A Balachandran, K Subramanian Gene and Cell Therapy: Biology and Applications, 147-194, 2018 | 1 | 2018 |
| Splice-Switching Antisense Oligonucleotides Targeting Extra-and Intracellular Domains of Epidermal Growth Factor Receptor in Cancer Cells AA Balachandran, P Raguraman, K Rahimizadeh, RN Veedu Biomedicines 11 (12), 3299, 2023 | | 2023 |
